Skip to main content Accessibility help
  • Print publication year: 2017
  • Online publication date: December 2017

Chapter 40 - Extended Management Following Resuscitation

from Section 4 - Specific Conditions Associated with Fetal and Neonatal Brain Injury
1.Benitz, WE, Frankel, LR, Stevenson, DK. The pharmacology of neonatal resuscitation and cardiopulmonary intensive care. II. Extended intensive care. West J Med 1986; 145: 4751.
2.van den Broek, MP, Groenendaal, F, Egberts, AC, Rademaker, CM. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet 2010; 49: 277–94.
3.Zanelli, S, Buck, M, Fairchild, K. Physiologic and pharmacologic considerations for hypothermia therapy in neonates. J Perinatol 2011; 31: 377–86.
4.Stevenson, DK, Benitz, WE. A practical approach to diagnosis and immediate care of the cyanotic neonate: stabilization and preparation for transfer to level III nursery. Clin Pediatr (Phila) 1987; 26: 325–31.
5.Bruce, DA. Effects of hyperventilation on cerebral blood flow and metabolism. Clin Perinatol 1984; 11: 673–80.
6.Walsh-Sukys, MC, Tyson, JE, Wright, LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105: 1420.
7.Kusuda, S, Shishida, N, Miyagi, N, et al. Cerebral blood flow during treatment for pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed 1999; 80: F30–3.
8.Gleason, CA, Short, BL, Jones, MD Jr. Cerebral blood flow and metabolism during and after prolonged hypocapnia in newborn lambs. J Pediatr 1989; 115: 309–14.
9.Liem, KD, Hopman, JC, Oeseburg, B, et al. Cerebral oxygenation and hemodynamics during induction of extracorporeal membrane oxygenation as investigated by near infrared spectrophotometry. Pediatrics 1995; 95: 555–61.
10.Toft, PB, Leth, H, Lou, HC, et al. Local vascular CO2 reactivity in the infant brain assessed by functional MRI. Pediatr Radiol 1995; 25: 420–4.
11.Chalak, LF, Tarumi, T, Zhang, R. The “neurovascular unit approach” to evaluate mechanisms of dysfunctional autoregulation in asphyxiated newborns in the era of hypothermia therapy. Early Hum Dev 2014; 90: 687–94.
12.Bifano, EM, Pfannenstiel, A. Duration of hyperventilation and outcome in infants with persistent pulmonary hypertension. Pediatrics 1988; 81: 657–61.
13.Hendricks-Munoz, KD, Walton, JP. Hearing loss in infants with persistent fetal circulation. Pediatrics 1988; 81: 650–6.
14.Leavitt, AM, Watchko, JF, Bennett, FC, Folsom, RC. Neurodevelopmental outcome following persistent pulmonary hypertension of the neonate. J Perinatol 1987; 7: 288–91.
15.Walsh-Sukys, MC, Cornell, DJ, Houston, LN, et al. Treatment of persistent pulmonary hypertension of the newborn without hyperventilation: an assessment of diffusion of innovation. Pediatrics 1994; 94: 303–6.
16.Wung, JT, James, LS, Kilchevsky, E, James, E. Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation. Pediatrics 1985; 76: 488–94.
17.Clark, RH, Yoder, BA, Sell, MS. Prospective, randomized comparison of high-frequency oscillation and conventional ventilation in candidates for extracorporeal membrane oxygenation. J Pediatr 1994; 124: 447–54.
18.Baumgart, S, Hirschl, RB, Butler, SZ, et al. Diagnosis-related criteria in the consideration of extracorporeal membrane oxygenation in neonates previously treated with high-frequency jet ventilation. Pediatrics 1992; 89: 491–4.
19.deLemos, R, Yoder, B, McCurnin, D, et al. The use of high-frequency oscillatory ventilation (HFOV) and extracorporeal membrane oxygenation (ECMO) in the management of the term/near term infant with respiratory failure. Early Hum Dev 1992; 29: 299303.
20.Bhuta, T, Henderson-Smart, DJ. Rescue high frequency oscillatory ventilation versus conventional ventilation for pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 1998; 2: CD000438.
21.Hintz, SR, Suttner, DM, Sheehan, AM, et al. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. Pediatrics 2000; 106: 1339–43.
22.Cools, F, Offringa, M. Meta-analysis of elective high frequency ventilation in preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1999; 80: F1520.
23.Henderson-Smart, DJ, Bhuta, T, Cools, F, Offringa, M. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2003; 4: CD000104.
24.Crone, RK, Favorito, J. The effects of pancuronium bromide on infants with hyaline membrane disease. J Pediatr 1980; 97: 991–3.
25.Goudsouzian, NG, Liu, LM, Savarese, JJ. Metocurine in infants and children: neuromuscular and clinical effects. Anesthesiology 1978; 49: 266–9.
26.Anand, KJ, Barton, BA, McIntosh, N, et al. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial: neonatal outcome and prolonged analgesia in neonates. Arch Pediatr Adolesc Med 1999; 153: 331–8.
27.Grunau, RE, Whitfield, MF, Petrie-Thomas, J, et al. Neonatal pain, parenting stress and interaction, in relation to cognitive and motor development at 8 and 18 months in preterm infants. Pain 2009; 143: 138–46.
28.Jobe, AH. Pulmonary surfactant therapy. N Engl J Med 1993; 328: 861–8.
29.Kendig, JW, Ryan, RM, Sinkin, RA, et al. Comparison of two strategies for surfactant prophylaxis in very premature infants: a multicenter randomized trial. Pediatrics 1998; 101: 1006–12.
30.Soll, RF. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 1998; 3: CD001149.
31.Bancalari, E, del Moral, T. Bronchopulmonary dysplasia and surfactant. Biol Neonate 2001; 80(Suppl 1): 713.
32.Greenough, A. Expanded use of surfactant replacement therapy. Eur J Pediatr 2000; 159: 635–40.
33.Lotze, A, Mitchell, BR, Bulas, DI, et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr 1998; 132: 40–7.
34.Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336: 597604.
35.Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 1997; 99: 838–45.
36.Van Meurs, KP, Wright, LL, Ehrenkranz, RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353: 1322.
37.Breitweser, JA, Meyer, RA, Sperling, MA, et al. Cardiac septal hypertrophy in hyperinsulinemic infants. J Pediatr 1980; 96: 535–9.
38.Seri, I. Systemic and pulmonary effects of vasopressors and inotropes in the neonate. Biol Neonate 2006; 89: 340–2.
39.Zaritsky, A, Chernow, B. Use of catecholamines in pediatrics. J Pediatr 1984; 105: 341–50.
40.Friedman, WF, George, BL. Treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr 1985; 106: 697706.
41.Bard, H. Hemoglobin synthesis and metabolism during the neonatal period. In Christensen, RD, ed., Hematologic Problems of the Neonate. Philadelphia: Saunders, 2000: 374–7.
42.Yeh, TF, Shibli, A, Leu, ST, et al. Early furosemide therapy in premature infants (less than or equal to 2000 g) with respiratory distress syndrome: a randomized, controlled trial. J Pediatr 1984; 105: 603–9.
43.Benitz, WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 2010; 30: 241–52.
44.Van Overmeire, B, Smets, K, Lecoutere, D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343: 674–81.
45.Fowlie, PW. Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2000; 2: CD000174.
46.Schmidt, B, Davis, P, Moddemann, D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344: 1966–72.
47.Ment, LR, Vohr, B, Allan, W, et al. Outcome of children in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics 2000; 105: 485–91.
48.Ment, LR, Vohr, BR, Makuch, RW, et al. Prevention of intraventricular hemorrhage by indomethacin in male preterm infants. J Pediatr 2004; 145: 832–4.
49.Clyman, RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate strategies. J Pediatr 1996; 128: 601–7.
50.Watterberg, KL, Gerdes, JS, Cole, CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114: 1649–57.
51.Heymann, MA. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease. Am Heart J 1981; 101: 837–43.
52.Brann, AW Jr., Myers, RE. Central nervous system findings in the newborn monkey following severe in utero partial asphyxia. Neurology 1975; 25: 327–38.
53.Myers, RE. Two patterns of perinatal brain damage and their conditions of occurrence. Am J Obstet Gynecol 1972; 112: 246–76.
54.Myers, RE. Experimental models of perinatal brain damage: relevance to human pathology. In Gluck, L, ed., Intrauterine Asphyxia and the Developing Fetal Brain. Chicago: Year Book, 1977: 3797.
55.Mujsce, DJ, Christensen, MA, Vannucci, RC. Cerebral blood flow and edema in perinatal hypoxic-ischemic brain damage. Pediatr Res 1990; 27: 450–3.
56.Young, RS, Yagel, SK. Cerebral physiological and metabolic effects of hyperventilation in the neonatal dog. Ann Neurol 1984; 16: 337–42.
57.Hill, A. Current concepts of hypoxic-ischemic cerebral injury in the term newborn. Pediatr Neurol 1991; 7: 317–25.
58.Lupton, BA, Hill, A, Roland, EH, et al. Brain swelling in the asphyxiated term newborn: pathogenesis and outcome. Pediatrics 1988; 82: 139–46.
59.Volpe, JJ. Hypoxic-ischemic encephalopathy. In Volpe, JJ, ed., Neurology of the Newborn. Philadelphia: Saunders, 2001: 217394.
60.Levene, MI, Evans, DH. Continuous measurement of subarachnoid pressure in the severely asphyxiated newborn. Arch Dis Child 1983; 58: 1013–5.
61.Levene, MI. Management and outcome of birth asphyxia. In Levene, MI, Lilforde, RJ, eds., Fetal and Neonatal Neurology and Neurosurgery. Edinburgh: Churchill Livingston, 1995: 427–42.
62.Levene, MI, Evans, DH, Forde, A, Archer, LN. Value of intracranial pressure monitoring of asphyxiated newborn infants. Dev Med Child Neurol 1987; 29: 311–9.
63.Rosenberg, AA, Jones, MD Jr, Traystman, RJ, et al. Response of cerebral blood flow to changes in PCO2 in fetal, newborn, and adult sheep. Am J Physiol 1982; 242: H862–6.
64.Bernbaum, JC, Russell, P, Sheridan, PH, et al. Long-term follow-up of newborns with persistent pulmonary hypertension. Crit Care Med 1984; 12: 579–83.
65.Wiswell, TE, Graziani, LJ, Kornhauser, MS, et al. Effects of hypocarbia on the development of cystic periventricular leukomalacia in premature infants treated with high-frequency jet ventilation. Pediatrics 1996; 98: 918–24.
66.Dammann, O, Allred, EN, Kuban, KC, et al. Hypocarbia during the first 24 postnatal hours and white matter echolucencies in newborns ≤28 weeks gestation. Pediatr Res 2001; 49: 388–93.
67.Vannucci, RC, Towfighi, J, Heitjan, DF, Brucklacher, RM. Carbon dioxide protects the perinatal brain from hypoxic-ischemic damage: an experimental study in the immature rat. Pediatrics 1995; 95: 868–74.
68.Vannucci, RC, Towfighi, J, Brucklacher, RM, Vannucci, SJ. Effect of extreme hypercapnia on hypoxic-ischemic brain damage in the immature rat. Pediatr Res 2001; 49: 799803.
69.Cooper, PR, Moody, S, Clark, WK, et al. Dexamethasone and severe head injury: a prospective double-blind study. J Neurosurg 1979; 51: 307–16.
70.Dearden, NM, Gibson, JS, McDowall, DG, et al. Effect of high-dose dexamethasone on outcome from severe head injury. J Neurosurg 1986; 64: 81–8.
71.Levene, MI, Evans, DH. Medical management of raised intracranial pressure after severe birth asphyxia. Arch Dis Child 1985; 60: 12–6.
72.Barks, JD, Post, M, Tuor, UI. Dexamethasone prevents hypoxic-ischemic brain damage in the neonatal rat. Pediatr Res 1991; 29: 558–63.
73.Tuor, UI, Simone, CS, Barks, JD, Post, M. Dexamethasone prevents cerebral infarction without affecting cerebral blood flow in neonatal rats. Stroke 1993; 24: 452–7.
74.National Institutes of Health Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation of Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1994; 273: 413–8.
75.Adhikari, M, Moodley, M, Desai, PK. Mannitol in neonatal cerebral oedema. Brain Dev 1990; 12: 349–51.
76.Marchal, C, Costagliolu, P, Leaveau, P, Wong, RJ. Treatment de la souffrance cerebrale neonatale d’orisivie anoxique par le mannitol. Rev Pediatr 1974; 9: 581–9.
77.Adamson, SJ, Alessandri, LM, Badawi, N, et al. Predictors of neonatal encephalopathy in full-term infants. BMJ 1995; 311: 598602.
78.Badawi, N, Kurinczuk, JJ, Keogh, JM, et al. Intrapartum risk factors for newborn encephalopathy: the Western Australian case-control study. BMJ 1998; 317: 1554–8.
79.Shankaran, S. The postnatal management of the asphyxiated term infant. Clin Perinatol 2002; 29: 675–92.
80.Shankaran, S, Laptook, AR, Pappas, A, et al. Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial. JAMA 2014; 312: 2629–39.
81.Svenningsen, NW, Blennow, G, Lindroth, M, et al. Brain-orientated intensive care treatment in severe neonatal asphyxia: effects of phenobarbitone protection. Arch Dis Child 1982; 57: 176–83.
82.Hall, RT, Hall, FK, Daily, DK. High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up. J Pediatr 1998; 132: 345–8.
83.Sarkar, S, Barks, JD, Bapuraj, JR, et al. Does phenobarbital improve the effectiveness of therapeutic hypothermia in infants with hypoxic-ischemic encephalopathy? J Perinatol 2012; 32: 1520.
84.Meyn, DF Jr, Ness, J, Ambalavanan, N, Carlo, WA. Prophylactic phenobarbital and whole-body cooling for neonatal hypoxic-ischemic encephalopathy. J Pediatr 2010; 157: 334–6.
85.Diaz, J, Schain, RJ. Phenobarbital: effects of long-term administration on behavior and brain of artificially reared rats. Science 1978; 199: 90–1.
86.Bittigau, P, Sifringer, M, Genz, K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA 2002; 99: 15089–94.
87.Miller, SP, Weiss, J, Barnwell, A, et al. Seizure-associated brain injury in term newborns with perinatal asphyxia. Neurology 2002; 58: 542–8.
88.Evans, DJ, Levene, MI, Tsakmakis, M. Anticonvulsants for preventing mortality and morbidity in full term newborns with perinatal asphyxia. Cochrane Database Syst Rev 2007; 3: D001240.
89.Giacoia, GP. Asphyxial brain damage in the newborn: new insights into pathophysiology and possible pharmacologic interventions. South Med J 1993; 86: 676–82.
90.Muir, KW, Lees, KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26: 503–13.
91.Levene, M. Role of excitatory amino acid antagonists in the management of birth asphyxia. Biol Neonate 1992; 62: 248–51.
92.Steinberg, GK, Bell, TE, Yenari, MA. Dose escalation safety and tolerance study of the N-methyl-d-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg 1996; 84: 860–6.
93.Davis, SM, Lees, KR, Albers, GW, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000; 31: 347–54.
94.Parikka, H, Toivonen, L, Naukkarinen, V, et al. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction. Eur Heart J 1999; 20: 111–20.
95.Lampl, Y, Gilad, R, Geva, D, et al. Intravenous administration of magnesium sulfate in acute stroke: a randomized double-blind study. Clin Neuropharmacol 2001; 24: 11–5.
96.Lucas, MJ, Leveno, KJ, Cunningham, FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995; 333: 201–5. Haan, HH, Gunn, AJ, Williams, CE, et al. Magnesium sulfate therapy during asphyxia in near-term fetal lambs does not compromise the fetus but does not reduce cerebral injury. Am J Obstet Gynecol 1997; 176: 1827.
98.Marret, S, Gressens, P, Gadisseux, JF, Evrard, P. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies. Dev Med Child Neurol 1995; 37: 473–84.
99.McDonald, JW, Silverstein, FS, Johnston, MV. Magnesium reduces N-methyl-d-aspartate (NMDA)–mediated brain injury in perinatal rats. Neurosci Lett 1990; 109: 234–8.
100.Penrice, J, Amess, PN, Punwani, S, et al. Magnesium sulfate after transient hypoxia-ischemia fails to prevent delayed cerebral energy failure in the newborn piglet. Pediatr Res 1997; 41: 443–7.
101.Levene, M, Blennow, M, Whitelaw, A, et al. Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia. Arch Dis Child Fetal Neonatal Ed 1995; 73: F174–7.
102.Robertson, NJ, Edwards, AD. Recent advances in developing neuroprotective strategies for perinatal asphyxia. Curr Opin Pediatr 1998; 10: 575–80.
103.Marret, S, Doyle, LW, Crowther, CA, Middleton, P. Antenatal magnesium sulphate neuroprotection in the preterm infant. Semin Fetal Neonatal Med 2007; 12: 311–7.
104.Crowther, CA, Hiller, JE, Doyle, LW, Haslam, RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized, controlled trial. JAMA 2003; 290: 2669–76.
105.Rouse, DJ, Hirtz, DG, Thom, E, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359: 895905.
106.American College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Maternal-Fetal Medicine. Magnesium sulfate before anticipated preterm birth for neuroprotection (Committee Opinion No. 455). Obstet Gynecol 2010; 115: 669–71.
107.Gunn, AJ, Mydlar, T, Bennet, L, et al. The neuroprotective actions of a calcium channel antagonist, flunarizine, in the infant rat. Pediatr Res 1989; 25: 573–6.
108.Gunn, AJ, Williams, CE, Mallard, EC, et al. Flunarizine, a calcium channel antagonist, is partially prophylactically neuroprotective in hypoxic-ischemic encephalopathy in the fetal sheep. Pediatr Res 1994; 35: 657–63.
109.Levene, MI, Gibson, NA, Fenton, AC, et al. The use of a calcium-channel blocker, nicardipine, for severely asphyxiated newborn infants. Dev Med Child Neurol 1990; 32: 567–74.
110.Buonocore, G, Groenendaal, F. Anti-oxidant strategies. Semin Fetal Neonatal Med 2007; 12: 287–95.
111.Palmer, C, Towfighi, J, Roberts, RL, Heitjan, DF. Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. Pediatr Res 1993; 33: 405–11.
112.Van Bel, F, Shadid, M, Moison, RM, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics 1998; 101: 185–93.
113.Benders, MJ, Bos, AF, Rademaker, CM, et al. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch Dis Child Fetal Neonatal Ed 2006; 91: F163–5.
114.Gunes, T, Ozturk, MA, Koklu, E, et al. Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatr Neurol 2007; 36: 1724.
115.Welin, AK, Svedin, P, Lapatto, R, et al. Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pediatr Res 2007; 61: 153–8.
116.Robertson, NJ, Faulkner, S, Fleiss, B, et al. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain 2013; 136: 90105.
117.Aly, H, Elmahdy, H, El-Dib, M, et al. Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. J Perinatol 2015; 35: 186–91.
118.Tan, WK, Williams, CE, Mallard, CE, Gluckman, PD. Monosialoganglioside GM1 treatment after a hypoxic-ischemic episode reduces the vulnerability of the fetal sheep brain to subsequent injuries. Am J Obstet Gynecol 1994; 170: 663–9.
119.Hall, ED. The neuroprotective pharmacology of methylprednisolone. J Neurosurg 1992; 76: 1322.
120.Amar, AP, Levy, ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 1999; 44: 1027–39; discussion 3940.
121.Hall, ED, McCall, JM, Means, ED. Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol 1994; 28: 221–68.
122.Kavanagh, RJ, Kam, PC. Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth 2001; 86: 110–9.
123.McPherson, RJ, Juul, SE. Recent trends in erythropoietin-mediated neuroprotection. Int J Dev Neurosci 2008; 26: 103–11.
124.Gonzalez, FF, McQuillen, P, Mu, D, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci 2007; 29: 321–30.
125.Wu, YW, Bauer, LA, Ballard, RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012; 130: 683–91.
126.Sabir, H, Bishop, S, Cohen, N, et al. Neither xenon nor fentanyl induces neuroapoptosis in the newborn pig brain. Anesthesiology 2013; 119: 345–57.
127.Ma, D, Hossain, M, Chow, A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol 2005; 58: 182–93.
128.Hobbs, C, Thoresen, M, Tucker, A, et al. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke 2008; 39: 1307–13.
129.Chakkarapani, E, Dingley, J, Aquilina, K, et al. Effects of xenon and hypothermia on cerebrovascular pressure reactivity in newborn global hypoxic-ischemic pig model. J Cereb Blood Flow Metab 2013; 33: 1752–60.
130.Dingley, J, Tooley, J, Liu, X, et al. Xenon ventilation during therapeutic hypothermia in neonatal encephalopathy: a feasibility study. Pediatrics 2014; 133: 809–18.
131.Osredkar, D, Toet, MC, van Rooij, LG, et al. Sleep-wake cycling on amplitude-integrated electroencephalography in term newborns with hypoxic-ischemic encephalopathy. Pediatrics 2005; 115: 327–32.
132.Hellstrom-Westas, L, Rosen, I, Svenningsen, NW. Predictive value of early continuous amplitude integrated EEG recordings on outcome after severe birth asphyxia in full term infants. Arch Dis Child Fetal Neonatal Ed 1995; 72: F34–8.
133.Toet, MC, Hellstrom-Westas, L, Groenendaal, F, et al. Amplitude integrated EEG 3 and 6 hours after birth in full term neonates with hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed 1999; 81: F1923.
134.Thoresen, M, Hellstrom-Westas, L, Liu, X, de Vries, LS. Effect of hypothermia on amplitude-integrated electroencephalogram in infants with asphyxia. Pediatrics 2010; 126: e131–9.
135.Ancora, G, Maranella, E, Grandi, S, et al. Early predictors of short term neurodevelopmental outcome in asphyxiated cooled infants: a combined brain amplitude integrated electroencephalography and near infrared spectroscopy study. Brain Dev 2013; 35: 2631.
136.Toet, MC, Lemmers, PM, van Schelven, LJ, van Bel, F. Cerebral oxygenation and electrical activity after birth asphyxia: their relation to outcome. Pediatrics 2006; 117: 333–9.